BRAF and melanoma: In this context, identifying alternative molecular markers such as HRD in acral or mucosal melanoma is critical, given how these tumors have low TMB and BRAF V600 alterations, and, therefore, these tumors have not benefited substantially from the recent advances in ICIs and BRAF/mitogen-activated protein kinase (MEK) inhibitors.